Valuation SCYNEXIS, Inc.

Stocks

Market Closed - Nasdaq 01:30:00 03/10/2026 am IST			5-day change	1st Jan Change
5.120 ^USD	-4.66%		+16.63%	+1.20%

28/09	SCYNEXIS, Inc. Receives Biomedical Advanced Research And Development Authority Contract Providing Up To $214 Million In Non-Dilutive Funding For The Development Of SCY-247	CI
22/09	SCYNEXIS, Inc. Announces Appointment of Steven K. Burke, M.D. to its Board of Directors, Effective September 18, 2026	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	174	50.94	82.97	45.92	26.54	50.94	-	-
Change	-	-70.72%	62.87%	-44.66%	-42.2%	91.95%	-	-
Enterprise Value (EV)	174	50.94	82.97	45.92	26.54	50.94	50.94	50.94
Change	-	-70.72%	62.87%	-44.66%	-42.2%	91.95%	0%	0%
P/E	-4.88x	-1.06x	1.6x	-2.75x	-3.72x	-1.76x	-2.21x	-3.08x
PBR	-	-	-	-	-	-	-	-
PEG	-	-0.1x	-0x	0x	0.1x	-0x	0.1x	0.1x
Capitalization / Revenue	13.2x	10x	0.59x	12.3x	1.29x	82.2x	7.63x	3.62x
EV / Revenue	0x	0x	0x	0x	0x	82.2x	7.63x	3.62x
EV / EBITDA	-	-	-	-	-	-	-	-
EV / EBIT	-0x	-0x	0x	-0x	-0x	-1.26x	-2.05x	-2.22x
EV / FCF	-	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-	-
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-10	-11.76	11.12	-3.52	-1.36	-2.91	-2.315	-1.66
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	13.16	5.091	140.1	3.746	20.6	0.6195	6.677	14.08
EBITDA	-	-85.15	-	-	-	-	-	-
EBIT ¹	-60.84	-85.76	72.67	-37.12	-16.07	-40.32	-24.83	-22.96
Net income ¹	-32.87	-62.81	67.04	-21.29	-8.609	-30.55	-32.43	-22.46
Net Debt	-	-	-	-	-	-	-	-
Reference price ²	48.800	12.480	17.840	9.680	5.059	5.120	5.120	5.120
Nbr of stocks (in thousands)	3,565	4,082	4,651	4,744	5,246	9,950	-	-
Announcement Date	29/03/22	31/03/23	28/03/24	12/03/25	04/03/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
SCYNEXIS, INC.	-1.76x	-	-	-	5.09Cr
ELI LILLY AND COMPANY	32.45x	11.78x	23.93x	0.61%	1,01900Cr
JOHNSON & JOHNSON	28.48x	6.32x	17.7x	2.09%	62TCr
ABBVIE INC.	33.26x	7.78x	16.08x	2.64%	46TCr
MERCK & CO., INC.	104.98x	5.87x	24.89x	2.36%	36TCr
ROCHE HOLDING AG	18.81x	4.58x	11.36x	2.9%	33TCr
NOVARTIS AG	19.83x	5.17x	12.78x	3.09%	27TCr
ASTRAZENECA PLC	20.02x	4.17x	11.86x	2.13%	24TCr
AMGEN INC.	25.46x	6.66x	11.86x	2.5%	22TCr
GILEAD SCIENCES, INC.	-43.78x	6.39x	24.97x	2.27%	18TCr
Average	23.78x	6.52x	17.27x	2.29%	36.97TCr
Weighted average by Cap.	31.80x	7.61x	18.61x	1.96%